Advanced search
1 file | 359.81 KB Add to list

The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment

Hannelore Denys (UGent) , Geert Braems (UGent) , Kathleen Lambein (UGent) , Patrick Pauwels (UGent) , An Hendrix (UGent) , Astrid De Boeck (UGent) , Veronique Mathieu, Marc Bracke (UGent) and Olivier De Wever (UGent)
(2009) CURRENT PHARMACEUTICAL DESIGN. 15(12). p.1373-1384
Author
Organization
Abstract
Emerging evidence points towards a key role of the extracellular matrix (ECM) during tumor progression and therapy resistance. Paradoxically, in today's routine of cancer management the ECM is not taken into account. It is the aim of the present review to broaden our understanding of the mechanisms of therapy resistance, taking the ECM as a presumptive central regulator. The stromal ecosystem drives the accumulation of ECM at the invasion front. Therefore, we address the question whether the detection of ECM signatures in histopathology and biofluids may help predicting therapy resistance and determining the prognosis of cancer. Since the ECM is an attractive target for tumor therapy, current therapeutic strategies in preclinical or clinical development will be discussed.
Keywords
BETA(1) INTEGRIN, GENE-EXPRESSION, INDUCED APOPTOSIS, GROWTH-FACTOR, HUMAN BREAST-CANCER, PROSTATE-SPECIFIC ANTIGEN, MOLECULE HEPARANASE INHIBITORS, CELL LUNG-CANCER, RESISTANCE CAM-DR, FOCAL ADHESION KINASE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 359.81 KB

Citation

Please use this url to cite or link to this publication:

MLA
Denys, Hannelore, et al. “The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment.” CURRENT PHARMACEUTICAL DESIGN, vol. 15, no. 12, 2009, pp. 1373–84.
APA
Denys, H., Braems, G., Lambein, K., Pauwels, P., Hendrix, A., De Boeck, A., … De Wever, O. (2009). The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. CURRENT PHARMACEUTICAL DESIGN, 15(12), 1373–1384.
Chicago author-date
Denys, Hannelore, Geert Braems, Kathleen Lambein, Patrick Pauwels, An Hendrix, Astrid De Boeck, Veronique Mathieu, Marc Bracke, and Olivier De Wever. 2009. “The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment.” CURRENT PHARMACEUTICAL DESIGN 15 (12): 1373–84.
Chicago author-date (all authors)
Denys, Hannelore, Geert Braems, Kathleen Lambein, Patrick Pauwels, An Hendrix, Astrid De Boeck, Veronique Mathieu, Marc Bracke, and Olivier De Wever. 2009. “The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment.” CURRENT PHARMACEUTICAL DESIGN 15 (12): 1373–1384.
Vancouver
1.
Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De Boeck A, et al. The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. CURRENT PHARMACEUTICAL DESIGN. 2009;15(12):1373–84.
IEEE
[1]
H. Denys et al., “The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment,” CURRENT PHARMACEUTICAL DESIGN, vol. 15, no. 12, pp. 1373–1384, 2009.
@article{678869,
  abstract     = {{Emerging evidence points towards a key role of the extracellular matrix (ECM) during tumor progression and therapy resistance. Paradoxically, in today's routine of cancer management the ECM is not taken into account. It is the aim of the present review to broaden our understanding of the mechanisms of therapy resistance, taking the ECM as a presumptive central regulator. The stromal ecosystem drives the accumulation of ECM at the invasion front. Therefore, we address the question whether the detection of ECM signatures in histopathology and biofluids may help predicting therapy resistance and determining the prognosis of cancer. Since the ECM is an attractive target for tumor therapy, current therapeutic strategies in preclinical or clinical development will be discussed.}},
  author       = {{Denys, Hannelore and Braems, Geert and Lambein, Kathleen and Pauwels, Patrick and Hendrix, An and De Boeck, Astrid and Mathieu, Veronique and Bracke, Marc and De Wever, Olivier}},
  issn         = {{1381-6128}},
  journal      = {{CURRENT PHARMACEUTICAL DESIGN}},
  keywords     = {{BETA(1) INTEGRIN,GENE-EXPRESSION,INDUCED APOPTOSIS,GROWTH-FACTOR,HUMAN BREAST-CANCER,PROSTATE-SPECIFIC ANTIGEN,MOLECULE HEPARANASE INHIBITORS,CELL LUNG-CANCER,RESISTANCE CAM-DR,FOCAL ADHESION KINASE}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{1373--1384}},
  title        = {{The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment}},
  volume       = {{15}},
  year         = {{2009}},
}

Web of Science
Times cited: